The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market

Davis Polk advised the sales agent in connection with a new SEC-registered at-the-marketing offering program by Oculis Holding AG under which Oculis Holding may sell up to an aggregate amount of $100 million of ordinary shares. Oculis Holding’s ordinary shares are traded on the Nasdaq Global Market and the Nasdaq Iceland Main Market under the symbol “OCS.”

Oculis is a global biopharmaceutical company headquartered in Lausanne, Switzerland. Its mission is to save sight, improve eye care and address medical needs with breakthrough innovations. Oculis’s pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments, focusing on areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED) and neuro-retina indications such as glaucoma affecting growing patient populations.

The Davis Polk corporate team included partner Derek Dostal and associates Arisa Akashi Sin, Wenyi Xu and Blair Shi. The tax team included counsel Yixuan Long and associate Ben Silver. The intellectual property team included partner David R. Bauer and associate Adrian Rabin. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.